Key result
Clinical and 5-gene signature model predicts lower-grade glioma survival with a ~0.75 C-statistic.
Why the study?
Prognostic models using m7G-related genes with good predictive performance for lower-grade gliomas had yet to be developed.
Cohort (n=1,010)
Yes
A novel prognostic model incorporating m7G-associated genes from tumor-associated macrophages and clinical variables successfully predicts overall survival in patients with lower-grade gliomas.
May refine lower-grade glioma prognostication; leaves open prospective validation before clinical use.
As the crucial component of the glioma microenvironment, tumor-associated macrophages (TAMs) significantly contribute to the immunosuppressive microenvironment and strongly influence glioma progression via various signaling molecules, simultaneously providing new insight into therapeutic strategies. Studies are aiming at developing prognostic models using N7-methylguanosine (m7G)-related genes in gliomas, however, models with good predictive performance for lower-grade gliomas have yet to be developed. Based on genes with m7G variants and clinical information, two prediction models have been derived to predict the probability of survival for patients with lower-grade gliomas in TCGA. The models were externally validated using independent datasets. Based on CGGA information, updated models that were created matched the features of the local population. Two models were derived, validated and updated. Model 1, which was derived on the basis of mRNA, only contains five genes: CD37, EIF3A, CALU, COLGALT1, and DDX3X. Model 2 included six variables: grade, age, gender, IDH mutation status, 1p/19q codeletion status and prognostic index of model 1. The C-statistic of revised model 1 was 0.764 (95% CI 0.730-0.798) in the revised set and 0.700 (95% CI 0.658-0.742) in the test set. Regarding internal validation, C-statistic for model 2 with 1000 bootstrap replications was 0.848, while in external validation, the C-statistic was 0.752 (95% CI 0.714-0.788). Both models exhibited satisfactory calibration after updating in external validation. The models' web calculator is provided at https://lhj0520.shinyapps.io/M7G-LGG_model/ .
No takes yet. Share an insight, caveat, or question.
Ao et al. (2025) conducted a cohort in Lower-grade gliomas (n=1,010). Prognostic model (Model 2) was evaluated on C-statistic for overall survival prediction (external validation) (95% CI 0.714-0.788). A prognostic model incorporating clinical variables and a 5-gene signature successfully predicted overall survival in patients with lower-grade gliomas, achieving a C-statistic of 0.752 in external validation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: